Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Diabetic Cardiac Autonomic Neuropathy
NCT06461377Phase 4Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of semaglutide in diabetic cardiac autonomic neuropathy (CAN) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Heart Rate Variability at 12 weeks. Started Jun 2024; status: recruiting.
02
Drugs
03
Conditions
diabetic cardiac autonomic neuropathy (CAN)
Beyond the preview
Go deeper on NCT06461377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06461377.